Connection
Barry Uretsky to Thrombosis
This is a "connection" page, showing publications Barry Uretsky has written about Thrombosis.
|
|
Connection Strength |
|
 |
|
 |
|
1.071 |
|
|
|
-
Singla S, Sachdeva R, Uretsky BF. The risk of adverse cardiac and bleeding events following noncardiac surgery relative to antiplatelet therapy in patients with prior percutaneous coronary intervention. J Am Coll Cardiol. 2012 Nov 13; 60(20):2005-16.
Score: 0.353
-
Uretsky BF. The value of recanalizing a chronic total occlusion. Catheter Cardiovasc Interv. 2011 Sep 01; 78(3):354-5.
Score: 0.327
-
Abdel-Karim AR, Uretsky BF. The importance of malapposition in angiographically optimized stenting in contemporaneous interventions. Expert Rev Cardiovasc Ther. 2018 Aug; 16(8):599-605.
Score: 0.131
-
Uretsky BF. All stent strut malappositions are not created equal. Catheter Cardiovasc Interv. 2018 02 15; 91(3):376-377.
Score: 0.128
-
Saeed M, Rahman A, Afzal A, Agoston I, Jammula P, Birnbaum Y, Ware DL, Uretsky BF, Schwarz ER, Rosanio S. Role of transesophageal echocardiography guided cardioversion in patients with atrial fibrillation, previous left atrial thrombus and effective anticoagulation. Int J Cardiol. 2006 Nov 18; 113(3):401-5.
Score: 0.057
-
Wiley JM, White CJ, Uretsky BF. Noncoronary complications of coronary intervention. Catheter Cardiovasc Interv. 2002 Oct; 57(2):257-65.
Score: 0.044
-
Garg R, Uretsky BF, Lev EI. Anti-platelet and anti-thrombotic approaches in patients undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv. 2007 Sep; 70(3):388-406.
Score: 0.015
-
Salinas G, Rangasetty UC, Uretsky BF, Birnbaum Y. The cycloxygenase 2 (COX-2) story: it's time to explain, not inflame. J Cardiovasc Pharmacol Ther. 2007 Jun; 12(2):98-111.
Score: 0.015